Watershed Asset Management L.L.C. Has $294,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Watershed Asset Management L.L.C. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 12.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,546 shares of the specialty pharmaceutical company’s stock after selling 1,348 shares during the period. Watershed Asset Management L.L.C.’s holdings in Collegium Pharmaceutical were worth $294,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. New York State Common Retirement Fund increased its stake in shares of Collegium Pharmaceutical by 1,475.5% in the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after buying an additional 188,347 shares during the period. Illinois Municipal Retirement Fund increased its stake in shares of Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock valued at $612,000 after buying an additional 411 shares during the period. Federated Hermes Inc. increased its stake in shares of Collegium Pharmaceutical by 76.0% in the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock valued at $6,549,000 after buying an additional 91,911 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Collegium Pharmaceutical by 28.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock valued at $272,000 after buying an additional 1,967 shares during the period. Finally, Everence Capital Management Inc. acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at $302,000.

Collegium Pharmaceutical Trading Up 3.5 %

Shares of NASDAQ:COLL traded up $1.20 during midday trading on Tuesday, hitting $35.94. The company had a trading volume of 618,658 shares, compared to its average volume of 431,744. Collegium Pharmaceutical, Inc. has a 12 month low of $20.83 and a 12 month high of $40.95. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 30.46 and a beta of 1.03. The firm has a fifty day simple moving average of $36.97 and a 200 day simple moving average of $31.11.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on COLL shares. Truist Financial lifted their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. StockNews.com raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Jefferies Financial Group restated a “hold” rating and issued a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Finally, Piper Sandler restated an “overweight” rating and issued a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.